FUNDAMENTALS · Fundamentals · AU Healthcare

Lumos Diagnostics Holdings (LDX) Fundamentals 2026 — Revenue Analysis | SniperIQ

Lumos Diagnostics Holdings (LDX) is a AU-listed Healthcare company in Medical - Specialties with a market capitalization of A$72M, trading at A$0.09 on the ASX. This SniperIQ fundamentals page covers Lumos Diagnostics Holdings's valuation, profitability (net margin -75.8%), revenue (

3M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA$72M
Net Margin-75.8%
Revenue (FY25)
3M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Lumos Diagnostics Holdings's market cap?

Lumos Diagnostics Holdings (LDX) has a market capitalization of approximately A$72M, trading at A$0.09 on the ASX. Market cap moves with the live share price.

What is Lumos Diagnostics Holdings's P/E ratio?

Lumos Diagnostics Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Lumos Diagnostics Holdings?

Lumos Diagnostics Holdings runs a net profit margin of -75.8%, a gross margin of 3.0%, and an operating margin of -81.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Lumos Diagnostics Holdings generate?

Lumos Diagnostics Holdings reported revenue of

3M for fiscal year 2025, with net income of -$7M and earnings per share (EPS) of -0.0106. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Lumos Diagnostics Holdings pay a dividend?

Lumos Diagnostics Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Lumos Diagnostics Holdings financially healthy?

Lumos Diagnostics Holdings carries a debt-to-equity ratio of 2.26x and a current ratio of 0.73x, with a market beta of 0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Lumos Diagnostics Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lumos Diagnostics Holdings (LDX) the key facts are: market cap A$72M, revenue

3M, 52-week range 0.06-0.33. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Lumos Diagnostics Holdings's full fundamentals live

Get Lumos Diagnostics Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Definitive Healthcare (DH) fundamentals · Mach7 Technologies (M7T) fundamentals · Cognition Therapeutics (CGTX) fundamentals · Neonc Technologies Holdings (NTHI) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons